Current Report Filing (8-k)
10 Mars 2023 - 10:49PM
Edgar (US Regulatory)
0001841330
false
0001841330
2023-03-10
2023-03-10
0001841330
KTTA:CommonStockParValue0.0001PerShareMember
2023-03-10
2023-03-10
0001841330
KTTA:WarrantsToPurchaseSharesOfCommonStockParValue0.0001PerShareMember
2023-03-10
2023-03-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 10, 2023
Pasithea Therapeutics Corp.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-40804 |
|
85-1591963 |
|
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
1111 Lincoln Road, Suite 500
Miami Beach, FL 33139
(Address of principal executive offices, including
zip code)
(702) 514-4174
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
| Title of Each Class: |
|
Trading Symbol |
|
Name of Each Exchange
on which Registered |
| Common Stock, par value $0.0001 per share |
|
KTTA |
|
The Nasdaq Capital Market |
| Warrants to purchase shares of common stock, par value $0.0001 per share |
|
KTTAW |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD.
Pasithea Therapeutics Corp. confirms that it does not hold any deposits
or securities or maintain any accounts at, or have any other banking relationship with, Silicon Valley Bank.
The information in this Item 7.01 is being furnished and shall not
be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration statement
or other document pursuant to the Securities Act of 1933, as amended.
Signature
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
PASITHEA THERAPEUTICS CORP. |
| |
|
|
| Dated: March 10, 2023 |
By: |
/s/ Tiago Reis Marques |
| |
|
Tiago Reis Marques |
| |
|
Chief Executive Officer |
Pasithea Therapeutics (NASDAQ:KTTA)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Pasithea Therapeutics (NASDAQ:KTTA)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
